Omaveloxolone

Omaveloxolone is a semisynthetic triterpenoid that works by a fundamentally different route from the coenzyme Q family. Instead of donating electrons or directly quenching radicals, it activates Nrf2, the transcription factor that governs a broad battery of antioxidant, anti-inflammatory, and mitochondrial bioenergetic genes, and it simultaneously suppresses the pro-inflammatory transcription factor NF-kappaB ^[1]. In Friedreich ataxia, frataxin deficiency leaves Nrf2 chronically suppressed, producing excess oxidative stress, mitochondrial dysfunction, and reduced ATP output; omaveloxolone is designed to correct that upstream deficit ^[1].

The pivotal evidence came from the two-part MOXIe study. In the dose-ranging portion, sixty-nine patients were randomized and the drug was well tolerated, with optimal pharmacodynamic changes at 80 to 160 mg per day; at 160 mg per day it improved the modified Friedreich Ataxia Rating Scale by 3.8 points versus baseline and by 2.3 points versus placebo, with even larger benefits in patients without musculoskeletal foot deformity ^[1]. The randomized, placebo-controlled MOXIe part 2 confirmed a significant mFARS benefit, and a delayed-start analysis of the open-label extension showed that the separation between early- and late-treated patients was preserved out to 144 weeks, arguing for a persistent effect on disease course rather than a transient symptomatic one ^[2].

Pharmacology studies in primates established dose-proportional exposure and robust induction of Nrf2 target genes in peripheral blood cells, liver, lung, and brain, and a pharmacokinetic-pharmacodynamic model linked those exposures to the clinically effective doses in patients ^[3]. On the strength of this program, omaveloxolone was approved as the first treatment for Friedreich ataxia. For the longevity and mitochondrial field it is a prominent proof of concept that boosting the body's own Nrf2-driven defenses can yield measurable neurological benefit.

Strong clinical evidence; FDA- and EMA-approved on the basis of randomized trials

In controlled trials omaveloxolone was generally well tolerated, with adverse events that were mostly mild; characteristic pharmacodynamic changes included reversible elevations in liver aminotransferases and reductions in ferritin, reflecting Nrf2 activation. Transaminase increases warrant liver monitoring, and the labeled therapy carries standard cautions around hepatic effects. Because it is a potent inducer of a broad transcriptional program, it is a prescription medicine that should be used under medical supervision and is not a casual supplement.

Omaveloxolone induces rather than inhibits, which is the reverse of what most people expect from a drug of its class. In healthy volunteers it cut midazolam exposure by roughly 45 percent, marking it as a moderate CYP3A4 inducer, and it also reduced exposure of CYP2C8 substrates and of BCRP and OATP1B1 substrates; rosuvastatin exposure fell by about 30 percent. Drugs that depend on those routes can become less effective alongside it.

Hormonal contraceptives are the clinically important case. Because they rely on CYP3A4 cleared steroids, omaveloxolone can reduce their reliability, and the labeling extends that warning to pills, patches, rings, implants and progestin only products alike.

In the other direction, omaveloxolone is itself a CYP3A4 substrate. Itraconazole and other strong inhibitors raise its exposure substantially, while the moderate inducer efavirenz lowers it. Grapefruit juice acts on the same enzyme in the gut wall.

Checking a whole stack? Run it through interactions + stacks.

Omaveloxolone was developed by Reata Pharmaceuticals as part of its family of Nrf2-activating oleanane triterpenoids, a lineage that also produced bardoxolone methyl. After the MOXIe trials in Friedreich ataxia, it received United States Food and Drug Administration approval in 2023 under the brand name Skyclarys, the first drug ever approved for that disease, followed by approval in the European Union. Reata was subsequently acquired by Biogen, which took over commercialization.

Omaveloxolone is widely regarded as a landmark success in mitochondrial and neurodegenerative therapeutics, being the first approved Friedreich ataxia treatment and a flagship example of Nrf2 activation translating into clinical benefit. In longevity circles the Nrf2 pathway is a heavily studied target, and omaveloxolone is often cited as the most clinically validated pharmacological Nrf2 activator to date. It is a serious prescription medicine rather than a wellness supplement, and its reputation rests on rigorous randomized evidence.